Publications

Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101.  Perazzolo S, Shireman LM, McConnachie LA, Koehn J, Kinman L, Lee W, Lane S, Collier AC, Shen DD, Ho RJY. J Pharm Sci. 2020 May; 109(5):1789-1801.

Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.  Perazzolo S, Shireman LM, Koehn J, McConnachie LA, Kraft JC, Shen DD, Ho RJY. J Pharm Sci. 2018 Dec;107(12):3153-3162.

Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates.  Koehn J, Iwamoto JF, Kraft JC, McConnachie LA, Collier AC, Ho RJY. AIDS. 2018 Nov 13;32(17):2463-2467.

Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection. McConnachie LA, Kinman LM, Koehn J, Kraft JC, Lane S, Lee W, Collier AC, Ho RJY. J Pharm Sci. 2018 Jul;107(7):1787-1790.

Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.  Kraft JC, McConnachie LA, Koehn J, Kinman L, Sun J, Collier AC, Collins C, Shen DD, Ho RJY. J Control Release. 2018 Apr 10;275:229-241.

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.  Kraft JC, McConnachie LA, Koehn J, Kinman L, Collins C, Shen DD, Collier AC, Ho RJ. AIDS. 2017 Mar 27;31(6):765-770.

Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.  Shao J, Kraft JC, Li B, Yu J, Freeling J, Koehn J, Ho RJ. Nanomedicine (Lond). 2016;11(5):545-64.

Systems Approach to targeted and long-acting HIV/AIDS therapy.  Ho RJ, Yu J, Li B, Kraft JC, Freeling JP, Koehn J, Shao J. Drug Deliv Transl Res. 2015 Dec;5(6):531-9.

A simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry.  Koehn J, Ding Y, Freeling J, Duan J, Ho RJ. Antimicrob Agents Chemother. 2015 Nov;59(11):6682-8.

Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.  Freeling JP, Koehn J, Shu C, Sun J, Ho RJ. AIDS Res Hum Retroviruses. 2015 Jan;31(1):107-14.

Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood.  Freeling JP, Koehn J, Shu C, Sun J, Ho RJ. AIDS. 2014 Nov 13;28(17):2625-7.

Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles.  Duan J, Freeling JP, Koehn J, Shu C, Ho RJ. J Pharm Sci. 2014 Aug;103(8):2520-9.

Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma.  Koehn J, Ho RJ. Antimicrob Agents Chemother. 2014 May;58(5):2675-80.